TRASTUZUMAB INDUCED CARDIOTOXICITY IN PATIENTS WITH HER2+BREAST CANCER

被引：0

作者：

Santamaria Elena, Capilla ^{[1
]}

Garcia Beatriz, Benitez ^{[1
]}

Jose Antonio, Romero Garrido ^{[1
]}

Aunon Pilar, Zamora ^{[2
]}

Abad Gema, Casado ^{[1
]}

del Valle Luis, Gonzalez ^{[1
]}

Ambrosio Alicia, Herrero ^{[1
]}

机构：

[1] Hosp Univ La Paz, Dept Pharm, Madrid, Spain

[2] Hosp Univ La Paz, Dept Oncol, Madrid, Spain

来源：

ATENCION FARMACEUTICA | 2013年 / 15卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: To assess the incidence of trastuzumab induced cardiotoxicity in clinical practice. Method: A retrospective study was conducted on HER2+ breast cancer patients who started treatment with trastuzumab in 2008 and 2009, and were monitored for one year. Results: 67 patients were included. The cardiotoxicity incidence was 46.3% with a mean time of onset from 5.5 +/- 3.3 months. The most commonly criterion was the decline in LVEF (Left Ventricular Ejection Fraction) >10 points from baseline value (28.4%). 45.1% of the cases were symptomatic cardiotoxicity. A baseline LVEF of >67% was associated with cardiotoxicity (p < 0.05). Conclusions: The incidence of cardiotoxicity in clinical practice was higher than that obtained in different clinical trials. It is necessary to reach consensus between professionals to ensure the drug's safety without limiting benefit for the patient.

引用

页码：261 / 267

页数：7

共 50 条

[21] Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+Breast Cancer
Song, Patrick N.
Mansur, Ameer
Lu, Yun
Della Manna, Deborah
Burns, Andrew
Samuel, Sharon
Heinzman, Katherine
Lapi, Suzanne E.
Yang, Eddy S.
Sorace, Anna G.
[J]. CANCERS, 2022, 14 (04)
[22] Inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+breast cancer
Miller, K. D.
Steding, C. E.
Prasad, N.
Rojas, L. A.
Herbert, B-S
[J]. CANCER RESEARCH, 2012, 72
[23] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
Esfahani, Khashayar
Ferrario, Cristiano
Le, Philippe
Panasci, Lawrence C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[24] Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+Breast Cancer
Castro-Guijarro, Ana Carla
Sanchez, Angel Matias
Flamini, Marina Ines
Vogel, Christoph F. A.
[J]. CANCERS, 2023, 15 (17)
[25] The trastuzumab era: current and upcoming targeted HER2+breast cancer therapies
Kreutzfeldt, Jordyn
Rozeboom, Brett
Dey, Nandini
De, Pradip
[J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (04): : 1045 - 1067
[26] A gene expression signature that predicts for trastuzumab response in HER2+breast cancer
Abukhdeir, Abde M.
Najor, Matthew S.
Turturro, Sanja B.
Armstrong, Andrew R.
McDonald, Andrew
Fogg, Lou
Cobleigh, Melody A.
[J]. CANCER RESEARCH, 2018, 78 (04)
[27] Trastuzumab Cardiotoxicity in Patients with Breast Cancer
Freitas, Aguinaldo Figueiredo, Jr.
Rassi, Salvador
[J]. ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2014, 102 (02) : 200 - 200
[28] Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2+breast cancer
Said, Badr Id
Chen, Hanbo
Jerzak, Katarzyna J.
Warner, Ellen
Myrehaug, Sten
Tseng, Chia-Lin
Detsky, Jay
Husain, Zain
Sahgal, Arjun
Soliman, Hany
[J]. JOURNAL OF NEURO-ONCOLOGY, 2022, 159 (01) : 177 - 183
[29] Factors associated with non use of adjuvant trastuzumab in older patients with HER2+breast cancer.
Luis, Ines Vaz
Lin, Nancy U.
Keating, Nancy Lynn
Barry, William Thomas
Lii, Joyce
Burstein, Harold J.
Winer, Eric P.
Freedman, Rachel A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[30] Study the synergistic role of trastuzumab along with docetaxel in immune profiling of HER2+breast cancer patients
Das, Ananya
Roy, Sraddhya
Nanda, Durgaprasad
Das, Subhadip
Chatterjee, Nabanita
[J]. FASEB JOURNAL, 2021, 35

← 1 2 3 4 5 →